BC ORIGINAL FORMULA OTC
Generic Name and Formulations:
Aspirin 650mg, caffeine 33.3mg, salicylamide 195mg; per powder; contains potassium 55mg/powder.
Prestige Brands, Inc.
Indications for BC ORIGINAL FORMULA:
Place powder on tongue and follow with liquid; or may stir into glass of water or other liquids. 1 powder every 3–4 hours; max: 4 powders/24 hours.
NSAID allergy. Viral infection in children and teenagers. 3rd trimester pregnancy.
History of asthma or peptic ulcer. Severe hepatic or renal dysfunction. Bleeding disorders. Diabetes. Gout. Pregnancy. Nursing mothers: not recommended.
Potentiates anticoagulants, hypoglycemics, methotrexate, acetazolamide, valproic acid, highly protein-bound drugs. Urinary alkalinizers, antacids, corticosteroids may increase excretion. May antagonize ACE inhibitors, β-blockers, diuretics, uricosurics. Increased bleeding risk with NSAIDs or chronic, heavy alcohol use. NSAIDs increase risk of renal dysfunction. Additive effects with other caffeine-containing products.
GI upset/bleed, prolonged bleeding time, anaphylaxis, salicylism.
Powder—2, 6, 18, 24, 50
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds